Investigators also appear to assess linvoseltamab in relapsed/refractory multiple myeloma as Component of the phase 3 LINKER-MM3 trial. Experimental: Dose expansion_sub-inhabitants 2_higher dose of niraparib MTDs and/or applicant RP2Ds for elimusertib applied together with niraparib at the next fixed dose. Qualifying aberrations have to be detected in possibly DNA or https://ericr114hji5.hazeronwiki.com/user